Rezolute announces further evidence of rz358's efficacy in tumor-mediated hyperinsulinism

Redwood city, calif., oct. 11, 2023 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results following administration of rz358 to a patient with refractory hypoglycemia due to tumor-mediated hyperinsulinism (tmhi) on a compassionate-use basis, under its expanded access program (eap).
RZLT Ratings Summary
RZLT Quant Ranking